Nanostics receives funding from the University of Alberta Innovation Fund to propel adoption of the ClarityDX Prostate test

Nanostics Inc., a precision health company developing diagnostic tests with its ClarityDX® platform technology, recently announced that it received an investment from the University of Alberta Innovation Fund (UAIF) to help propel adoption of Nanostics' ClarityDX® test in North America. The ClarityDX Prostate test, launched in Canada in September 2023, is available to patients from Nanostics' accredited clinical laboratory in Edmonton, Alberta.

This innovative blood test, which uses biological data, clinical information, and machine learning models to generate a risk score for aggressive prostate cancer, marks a significant advancement in prostate cancer screening. It provides critical support to men and their healthcare providers in making more informed decisions about whether additional screening is required following a high prostate-specific antigen (PSA) test result.

Nanostics Precision Health presented at the OBIO® Investment Summit.